Skip to main content

Table 2 Associated factors with intubation in 256 patients with COVID-19 treated with HFNO

From: Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study

 

Odds ratio (95% CI)

P value1

Non-respiratory SOFA score

1.78 (1.41-2.35)

<0.01

ROX index

0.53 (0.38-0.72)

<0.01

pH, per 0.1-unit increase

0.47 (0.24-0.86)

0.03

Leucocyte count, 109/μL

1.07 (1.001-1.13)

0.01

Malignancy

0.14 (0.02-0.88)

0.04

BMI, kg/m2

1.05 (0.97-1.14)

0.23

PaO2/FiO2 (per 10-point increase)

1.04 (0.97-1.11)

0.21

Gender (female)

1.60 (0.73-3.54)

0.24

D-dimer, U/L

1.00 (0.99-1.00)

0.31

APACHE II

0.95 (0.87-1.04)

0.26

Glasgow Coma Scale

0.51 (0.10-1.08)

0.34

Respiratory rate, rpm

0.97 (0.90-1.04)

0.50

Heart rate, bpm (per 10-bpm increase)

1.08 (0.87-1.35)

0.46

Time from symptom onset to ICU admission (per 1-day increase)

1.02 (0.95-1.12)

0.64

SBP, mmHg (per 10-mmHg increase)

0.96 (0.80-1.14)

0.66

PaCO2, mmHg (per 5-mmHg increase)

1.03 (0.87-1.21)

0.76

  1. 1Based on a multivariable logistic regression model after multiple imputation, 2 subjects were excluded for extensive missing data (>50% variables)
  2. CI confidence interval; HFNO high flow nasal oxygen treatment; SOFA Sequential Organ Failure Assessment; SBP systolic blood pressure; BMI body mass index; SpO2 peripheral oxyhemoglobin saturation; ICU intensive care unit; PaO2/FiO2 partial pressure of arterial oxygen to inspiratory oxygen ratio; APACHE Acute Physiology and Chronic Health Evaluation II; PaCO2 partial pressure of carbon dioxide; AIC Akaike information criterion